Clinical trial • Not applicable • Infectious Disease | Musculoskeletal

VANCOMYCIN for Total joint replacement (hip or knee)

Not applicable trial of VANCOMYCIN for Total joint replacement (hip or knee).

Overview

Trial Therapeutic Area
Infectious Disease | Musculoskeletal
Trial Disease
Total joint replacement (hip or knee)
Trial Stage
Not applicable
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
25-06-2024
First CTIS Authorization Date
08-10-2024

Trial design

Randomised, open-label, arms compare irrigation solutions and local antibiotic: povidone-iodine irrigation (0.35% pi) versus normal saline irrigation; chlorhexidine irrigation (0.05%) versus normal saline irrigation; local vancomycin (topical/local vancomycin, product record lists max total amount 2 g) versus no local vancomycin. (arms are described as combinations of lavage type with/without local vancomycin.)-controlled Not applicable trial across 13 sites in Spain.

Randomised
Yes
Open Label
Yes
Comparator
Arms compare irrigation solutions and local antibiotic: Povidone-iodine irrigation (0.35% PI) versus normal saline irrigation; Chlorhexidine irrigation (0.05%) versus normal saline irrigation; local vancomycin (topical/local vancomycin, product record lists max total amount 2 g) versus no local vancomycin. (Arms are described as combinations of lavage type with/without local vancomycin.)
Target Sample Size
325
Trial Duration For Participant
365

Eligibility

Recruits 325 No vulnerable population selected. Informed consent is required; 'Did not provide informed consent.' is listed as an exclusion. No assent or minor-specific procedures are indicated in the record..

Vulnerable Population
No vulnerable population selected. Informed consent is required; 'Did not provide informed consent.' is listed as an exclusion. No assent or minor-specific procedures are indicated in the record.

Inclusion criteria

  • {"criterion_text":"- Patients 18 years of age or older."}
  • {"criterion_text":"- Undergoing primary or aseptic revision TJR"}

Exclusion criteria

  • {"criterion_text":"- Received antibiotics for any reason in the two weeks prior to their TJR."}
  • {"criterion_text":"- Prior enrollment in the trial including the pilot study."}
  • {"criterion_text":"- Any condition or circumstance, which in the opinion of the Investigator, interferes with assessments or completion of the trial."}
  • {"criterion_text":"- A contraindication to study interventions."}
  • {"criterion_text":"- Chronic or acute infection at or near the TJR site."}
  • {"criterion_text":"- Prior history of periprosthetic joint infection including any reoperation due to infection."}
  • {"criterion_text":"- Undergoing surgery for a diagnosis of a fracture."}
  • {"criterion_text":"- Open infected wounds on affected limb"}
  • {"criterion_text":"- Undergoing bilateral TJR."}
  • {"criterion_text":"- Currently enrolled in a study that does not permit co-enrollment"}
  • {"criterion_text":"- Did not provide informed consent."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The primary outcome is infection that requires reoperation within 12 months of TJR.","definition_or_measurement_approach":"Reoperation due to infection within 12 months of primary or aseptic revision hip or knee total joint replacement; measured as occurrence of infection requiring reoperation within 12 months."}

Recruitment

Planned Sample Size
325
Recruitment Window Months
36
Consent Approach
Informed consent required from adult participants (18 years and older). 'Did not provide informed consent.' is listed as an exclusion. Subject information and informed consent form documents are available in Spanish (e.g. 'L1_SIS and ICF_Annex 1_Spanish_clean', 'L1_SIS and ICF General_Spanish_clean'). No assent procedures or minor consent documents are indicated.

Geography

Total Number Of Sites
13
Total Number Of Participants
325

Spain

Earliest CTIS Part Ii Submission Date
09-07-2024
Latest Decision Or Authorization Date
27-04-2026
Processing Time Days
657
Number Of Sites
13
Number Of Participants
325

Sites

Site Name
Hospital General Universitario Gregorio Maranon
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Pablo Sanz Ruiz
Principal Investigator Email
psanzr@salud.madrid.org
Contact Person Name
Pablo Sanz Ruiz
Contact Person Email
psanzr@salud.madrid.org
Site Name
Hospital Universitario Principe De Asturias
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Ana Castel Oñate
Principal Investigator Email
ana.castel@salud.madrid.org
Contact Person Name
Ana Castel Oñate
Contact Person Email
ana.castel@salud.madrid.org
Site Name
Hospital Universitario Infanta Leonor
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Ricardo Larrainzar Garijo
Principal Investigator Email
Ricardo.larrainzar@salud.madrid.org
Contact Person Name
Ricardo Larrainzar Garijo
Site Name
Hospital Universitari Vall D Hebron
Department Name
Orthopedic Surgery and Traumatology Service (Hip Unit)
Principal Investigator Name
María Mercedes Reverté
Principal Investigator Email
mariamercedes.reverte@vallhebron.cat
Contact Person Name
María Mercedes Reverté
Site Name
Hospital Clinic De Barcelona
Department Name
Orthopedic Surgery and Traumatology Service (Hip Unit)
Principal Investigator Name
Ernesto Muñoz
Principal Investigator Email
e.munoz.mahamud@gmail.com
Contact Person Name
Ernesto Muñoz
Contact Person Email
e.munoz.mahamud@gmail.com
Site Name
Hospital Clinic De Barcelona
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Juan Carlos Martinez
Principal Investigator Email
Jcmartin@clinic.cat
Contact Person Name
Juan Carlos Martinez
Contact Person Email
Jcmartin@clinic.cat
Site Name
Hospital Universitari Vall D Hebron
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Ernesto Guerra
Principal Investigator Email
ernestomelchor.guerra@vallhebron.cat
Contact Person Name
Ernesto Guerra
Site Name
Parc Sanitari Sant Joan De Deu
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Sara Castellanos Alonso
Principal Investigator Email
sara.castellanos@sjd.es
Contact Person Name
Sara Castellanos Alonso
Contact Person Email
sara.castellanos@sjd.es
Site Name
Consorci Sanitari De Terrassa
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Javier Alonso Rodríguez Piedra
Principal Investigator Email
8846@cst.cat
Contact Person Name
Javier Alonso Rodríguez Piedra
Contact Person Email
8846@cst.cat
Site Name
Consorci Sanitari De L'Alt Penedes I Garraf
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Alfred Dealbert
Principal Investigator Email
adealbert@csapg.cat
Contact Person Name
Alfred Dealbert
Contact Person Email
adealbert@csapg.cat
Site Name
Fundacio Assistencial De Mutua De Terrassa Fpc
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Margarita Veloso Duran
Principal Investigator Email
mveloso@mutuaterrassa.es
Contact Person Name
Margarita Veloso Duran
Contact Person Email
mveloso@mutuaterrassa.es
Site Name
Hospital Universitario La Paz
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Eduardo García Rey
Principal Investigator Email
egrey@salud.madrid.org
Contact Person Name
Eduardo García Rey
Contact Person Email
egrey@salud.madrid.org
Site Name
Hospital San Juan De Dios Santurtzi
Department Name
Orthopedic Surgery and Traumatology Service (Knee Unit)
Principal Investigator Name
Jesús Moreta
Principal Investigator Email
ospitaleasanturtzi.vconsultas@sjd.es
Contact Person Name
Jesús Moreta

Sponsor

Primary sponsor

Full Name
Hamilton Health Sciences Corporation
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Canada

Investigational products

Investigational Product Name
VANCOMYCIN
Active Substance
VANCOMYCIN
Modality
Small molecule
Routes Of Administration
CUTANEOUS USE
Route
CUTANEOUS USE
Authorisation Status
2
Maximum Dose
2 g
Investigational Product Name
CHLORHEXIDINE
Active Substance
BENZALKONIUM CHLORIDE; CHLORHEXIDINE GLUCONATE; BENZYL ALCOHOL
Modality
Small molecule
Routes Of Administration
CUTANEOUS USE
Route
CUTANEOUS USE
Authorisation Status
2
Starting Dose
0.05% (W/V) percent weight/volume
Maximum Dose
0.05% (W/V)
Investigational Product Name
POVIDONE
Active Substance
POVIDONE
Modality
Small molecule
Routes Of Administration
CUTANEOUS USE
Route
CUTANEOUS USE
Authorisation Status
2
Starting Dose
0.35% percent
Maximum Dose
0.35%
Investigational Product Name
Normal saline
Modality
Small molecule
Routes Of Administration
CUTANEOUS USE
Route
CUTANEOUS USE
Authorisation Status
2
Starting Dose
0.9% (W/V) percent weight/volume
Maximum Dose
0.9% (W/V)
Combination Treatment
Yes

Related trials

Other published trials that may interest you.